Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers

Erik S. Linklater, Elizabeth A. Tovar, Curt J. Essenburg, Lisa Turner, Zachary Madaj, Mary E. Winn, Marianne K. Melnik, Hasan Korkaya, Christiane R. Maroun, James G. Christensen, Matthew R. Steensma, Julie L. Boerner, Carrie R. Graveel

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

There is a vital need for improved therapeutic strategies that are effective in both primary and metastatic triple-negative breast cancer (TNBC). Current treatment options for TNBC patients are restricted to chemotherapy; however tyrosine kinases are promising druggable targets due to their high expression in multiple TNBC subtypes. Since coexpression of receptor tyrosine kinases (RTKs) can promote signaling crosstalk and cell survival in the presence of kinase inhibitors, it is likely that multiple RTKs will need to be inhibited to enhance therapeutic benefit and prevent resistance. The MET and EGFR receptors are actionable targets due to their high expression in TNBC; however crosstalk between MET and EGFR has been implicated in therapeutic resistance to single agent use of MET or EGFR inhibitors in several cancer types. Therefore it is likely that dual inhibition of MET and EGFR is required to prevent crosstalk signaling and acquired resistance. In this study, we evaluated the heterogeneity of MET and EGFR expression and activation in primary and metastatic TNBC tumorgrafts and determined the efficacy of MET (MGCD265 or crizotinib) and/or EGFR (erlotinib) inhibition against TNBC progression. Here we demonstrate that combined MET and EGFR inhibition with either MGCD265 and erlotinib treatment or crizotinib and erlotinib treatment were highly effective at abrogating tumor growth and significantly decreased the variability in treatment response compared to monotherapy. These results advance our understanding of the RTK signaling architecture in TNBC and demonstrate that combined MET and EGFR inhibition may be a promising therapeutic strategy for TNBC patients.

Original languageEnglish (US)
Pages (from-to)69903-69915
Number of pages13
JournalOncotarget
Volume7
Issue number43
DOIs
StatePublished - Jan 1 2016

Fingerprint

Triple Negative Breast Neoplasms
Receptor Protein-Tyrosine Kinases
Therapeutics
Protein-Tyrosine Kinases
Neoplasms
Cell Survival
Phosphotransferases
Drug Therapy

Keywords

  • EGFR
  • MET
  • Receptor tyrosine kinase
  • Triple-negative breast cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology

Cite this

Linklater, E. S., Tovar, E. A., Essenburg, C. J., Turner, L., Madaj, Z., Winn, M. E., ... Graveel, C. R. (2016). Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget, 7(43), 69903-69915. https://doi.org/10.18632/oncotarget.12065

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. / Linklater, Erik S.; Tovar, Elizabeth A.; Essenburg, Curt J.; Turner, Lisa; Madaj, Zachary; Winn, Mary E.; Melnik, Marianne K.; Korkaya, Hasan; Maroun, Christiane R.; Christensen, James G.; Steensma, Matthew R.; Boerner, Julie L.; Graveel, Carrie R.

In: Oncotarget, Vol. 7, No. 43, 01.01.2016, p. 69903-69915.

Research output: Contribution to journalArticle

Linklater, ES, Tovar, EA, Essenburg, CJ, Turner, L, Madaj, Z, Winn, ME, Melnik, MK, Korkaya, H, Maroun, CR, Christensen, JG, Steensma, MR, Boerner, JL & Graveel, CR 2016, 'Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers', Oncotarget, vol. 7, no. 43, pp. 69903-69915. https://doi.org/10.18632/oncotarget.12065
Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME et al. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget. 2016 Jan 1;7(43):69903-69915. https://doi.org/10.18632/oncotarget.12065
Linklater, Erik S. ; Tovar, Elizabeth A. ; Essenburg, Curt J. ; Turner, Lisa ; Madaj, Zachary ; Winn, Mary E. ; Melnik, Marianne K. ; Korkaya, Hasan ; Maroun, Christiane R. ; Christensen, James G. ; Steensma, Matthew R. ; Boerner, Julie L. ; Graveel, Carrie R. / Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. In: Oncotarget. 2016 ; Vol. 7, No. 43. pp. 69903-69915.
@article{840734e47c8a45f7881baa2b03df6d0f,
title = "Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers",
abstract = "There is a vital need for improved therapeutic strategies that are effective in both primary and metastatic triple-negative breast cancer (TNBC). Current treatment options for TNBC patients are restricted to chemotherapy; however tyrosine kinases are promising druggable targets due to their high expression in multiple TNBC subtypes. Since coexpression of receptor tyrosine kinases (RTKs) can promote signaling crosstalk and cell survival in the presence of kinase inhibitors, it is likely that multiple RTKs will need to be inhibited to enhance therapeutic benefit and prevent resistance. The MET and EGFR receptors are actionable targets due to their high expression in TNBC; however crosstalk between MET and EGFR has been implicated in therapeutic resistance to single agent use of MET or EGFR inhibitors in several cancer types. Therefore it is likely that dual inhibition of MET and EGFR is required to prevent crosstalk signaling and acquired resistance. In this study, we evaluated the heterogeneity of MET and EGFR expression and activation in primary and metastatic TNBC tumorgrafts and determined the efficacy of MET (MGCD265 or crizotinib) and/or EGFR (erlotinib) inhibition against TNBC progression. Here we demonstrate that combined MET and EGFR inhibition with either MGCD265 and erlotinib treatment or crizotinib and erlotinib treatment were highly effective at abrogating tumor growth and significantly decreased the variability in treatment response compared to monotherapy. These results advance our understanding of the RTK signaling architecture in TNBC and demonstrate that combined MET and EGFR inhibition may be a promising therapeutic strategy for TNBC patients.",
keywords = "EGFR, MET, Receptor tyrosine kinase, Triple-negative breast cancer, Tyrosine kinase inhibitors",
author = "Linklater, {Erik S.} and Tovar, {Elizabeth A.} and Essenburg, {Curt J.} and Lisa Turner and Zachary Madaj and Winn, {Mary E.} and Melnik, {Marianne K.} and Hasan Korkaya and Maroun, {Christiane R.} and Christensen, {James G.} and Steensma, {Matthew R.} and Boerner, {Julie L.} and Graveel, {Carrie R.}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.12065",
language = "English (US)",
volume = "7",
pages = "69903--69915",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "43",

}

TY - JOUR

T1 - Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers

AU - Linklater, Erik S.

AU - Tovar, Elizabeth A.

AU - Essenburg, Curt J.

AU - Turner, Lisa

AU - Madaj, Zachary

AU - Winn, Mary E.

AU - Melnik, Marianne K.

AU - Korkaya, Hasan

AU - Maroun, Christiane R.

AU - Christensen, James G.

AU - Steensma, Matthew R.

AU - Boerner, Julie L.

AU - Graveel, Carrie R.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - There is a vital need for improved therapeutic strategies that are effective in both primary and metastatic triple-negative breast cancer (TNBC). Current treatment options for TNBC patients are restricted to chemotherapy; however tyrosine kinases are promising druggable targets due to their high expression in multiple TNBC subtypes. Since coexpression of receptor tyrosine kinases (RTKs) can promote signaling crosstalk and cell survival in the presence of kinase inhibitors, it is likely that multiple RTKs will need to be inhibited to enhance therapeutic benefit and prevent resistance. The MET and EGFR receptors are actionable targets due to their high expression in TNBC; however crosstalk between MET and EGFR has been implicated in therapeutic resistance to single agent use of MET or EGFR inhibitors in several cancer types. Therefore it is likely that dual inhibition of MET and EGFR is required to prevent crosstalk signaling and acquired resistance. In this study, we evaluated the heterogeneity of MET and EGFR expression and activation in primary and metastatic TNBC tumorgrafts and determined the efficacy of MET (MGCD265 or crizotinib) and/or EGFR (erlotinib) inhibition against TNBC progression. Here we demonstrate that combined MET and EGFR inhibition with either MGCD265 and erlotinib treatment or crizotinib and erlotinib treatment were highly effective at abrogating tumor growth and significantly decreased the variability in treatment response compared to monotherapy. These results advance our understanding of the RTK signaling architecture in TNBC and demonstrate that combined MET and EGFR inhibition may be a promising therapeutic strategy for TNBC patients.

AB - There is a vital need for improved therapeutic strategies that are effective in both primary and metastatic triple-negative breast cancer (TNBC). Current treatment options for TNBC patients are restricted to chemotherapy; however tyrosine kinases are promising druggable targets due to their high expression in multiple TNBC subtypes. Since coexpression of receptor tyrosine kinases (RTKs) can promote signaling crosstalk and cell survival in the presence of kinase inhibitors, it is likely that multiple RTKs will need to be inhibited to enhance therapeutic benefit and prevent resistance. The MET and EGFR receptors are actionable targets due to their high expression in TNBC; however crosstalk between MET and EGFR has been implicated in therapeutic resistance to single agent use of MET or EGFR inhibitors in several cancer types. Therefore it is likely that dual inhibition of MET and EGFR is required to prevent crosstalk signaling and acquired resistance. In this study, we evaluated the heterogeneity of MET and EGFR expression and activation in primary and metastatic TNBC tumorgrafts and determined the efficacy of MET (MGCD265 or crizotinib) and/or EGFR (erlotinib) inhibition against TNBC progression. Here we demonstrate that combined MET and EGFR inhibition with either MGCD265 and erlotinib treatment or crizotinib and erlotinib treatment were highly effective at abrogating tumor growth and significantly decreased the variability in treatment response compared to monotherapy. These results advance our understanding of the RTK signaling architecture in TNBC and demonstrate that combined MET and EGFR inhibition may be a promising therapeutic strategy for TNBC patients.

KW - EGFR

KW - MET

KW - Receptor tyrosine kinase

KW - Triple-negative breast cancer

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84994309157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994309157&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12065

DO - 10.18632/oncotarget.12065

M3 - Article

VL - 7

SP - 69903

EP - 69915

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -